- Home
- ETNB vs TXG Comparison
ETNB vs TXG Comparison
Compare ETNB & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- TXG
- Stock Information
- Founded
- ETNB 2018
- TXG 2012
- Country
- ETNB United States
- TXG United States
- Employees
- ETNB N/A
- TXG N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- TXG Biotechnology: Laboratory Analytical Instruments
- Sector
- ETNB Health Care
- TXG Industrials
- Exchange
- ETNB Nasdaq
- TXG Nasdaq
- Market Cap
- ETNB 1.2B
- TXG 1.3B
- IPO Year
- ETNB 2019
- TXG 2019
- Fundamental
- Price
- ETNB $6.80
- TXG $8.67
- Analyst Decision
- ETNB Strong Buy
- TXG Buy
- Analyst Count
- ETNB 10
- TXG 16
- Target Price
- ETNB $27.56
- TXG $20.00
- AVG Volume (30 Days)
- ETNB 2.1M
- TXG 3.0M
- Earning Date
- ETNB 05-08-2025
- TXG 04-29-2025
- Dividend Yield
- ETNB N/A
- TXG N/A
- EPS Growth
- ETNB N/A
- TXG N/A
- EPS
- ETNB N/A
- TXG N/A
- Revenue
- ETNB N/A
- TXG $610,785,000.00
- Revenue This Year
- ETNB N/A
- TXG $1.43
- Revenue Next Year
- ETNB N/A
- TXG $8.86
- P/E Ratio
- ETNB N/A
- TXG N/A
- Revenue Growth
- ETNB N/A
- TXG N/A
- 52 Week Low
- ETNB $5.99
- TXG $8.54
- 52 Week High
- ETNB $11.84
- TXG $37.74
- Technical
- Relative Strength Index (RSI)
- ETNB 36.28
- TXG 30.53
- Support Level
- ETNB $7.66
- TXG $9.65
- Resistance Level
- ETNB $9.32
- TXG $10.60
- Average True Range (ATR)
- ETNB 0.73
- TXG 0.52
- MACD
- ETNB -0.12
- TXG -0.07
- Stochastic Oscillator
- ETNB 3.59
- TXG 5.58
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).